Training program for Myotonic Dystrophy

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Groupe de recherche interdisciplinaire sur les maladies neuromusculaires, Saguenay, Canada
Myotonic Dystrophy+1 More
Training program - Other
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

20 women with myotonic dystrophy type 1 (DM1) will complete a 12-week lower-limb strength training program. The training program consist of 3 series of 6 to 8 maximal repetitions of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. Training sessions will be closely supervise and take place twice a week. It is hypothesize that the training program will induce muscular hypertrophy despite the genetic defect. The training program should also have positive effects on function. The participants will be evaluated at baseline, week 6, week 12, month 6 and month 9 to quantify the effects of the training program and if these effects will be maintained over time.

Eligible Conditions

  • Myotonic Dystrophy
  • Myotonic Dystrophy 1

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 37 Secondary · Reporting Duration: At baseline, week 6, week 12, month 6 and month 9

Week 12
Change in blood test : biochemical (CK, Protein C reactive, leukocytes, cytokines, etc.)
Change in saliva sample : exercise biomarkers (-Omics markers)
Change in urine sample : exercise biomarkers (-Omics markers)
Changes in maximal isometric grip strength
Changes in maximal isometric muscle strength of the ankle dorsiflexors
Changes in maximal isometric muscle strength of the hip abductors
Changes in maximal isometric muscle strength of the hip extensors
Changes in maximal isometric muscle strength of the hip flexors
Changes in maximal isometric muscle strength of the knee flexors
Changes in muscle biopsy of the vastus lateralis: Nuclear foci
Changes in muscle biopsy of the vastus lateralis: mitochondrial function
Changes in muscle biopsy of the vastus lateralis: muscle fiber size
Changes in muscle biopsy of the vastus lateralis: muscle fiber typing
Changes in muscle biopsy of the vastus lateralis: muscle proteomics
Changes in muscle biopsy of the vastus lateralis: muscle transcriptomics
Month 9
Changes in the Marin apathy scale
Changes in the score of the lower extremity functional scale
Month 9
Change in the number of falls
Week 12
Changes in 1-repetition maximum strength of the hip abduction exercise
Changes in 1-repetition maximum strength of the leg extension exercise
Changes in 1-repetition maximum strength of the leg press exercise
Changes in 1-repetition maximum strength of the squat exercise
Month 6
Changes in the Hospital Anxiety and Depression Scale
Month 9
Change of the center of pressure parameters in static posturography : closed eyes bipodal position
Change of the center of pressure parameters in static posturography : open eyes bipodal position
Change of the center of pressure parameters in static posturography : open eyes semi-tandem position
Change of the center of pressure parameters in static posturography : open eyes tandem position
Month 6
Changes in maximal isometric muscle strength of the knee extensors
Month 9
Change in the score of the Brief Pain Inventory
Changes in comfortable walking speed in the 10-meter walk test
Changes in maximal walking speed in the 10-meter walk test
Changes in the number of repetitions in the 30-seconds sit-to-stand test
Changes in the score of the Fatigue and Daytime Sleepiness Scale
Changes in the score of the myotonic dystrophy health index
Changes in the time to perform of the Timed Up and Go
Changes in the time to perform the Timed stair test
Month 9
Change in score of the DM1-Activ questionnaire
At week 12
Self-perceived changes in daily life

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Training program
1 of 1
Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: Training program · No Placebo Group · N/A

Training program
Other
Experimental Group · 1 Intervention: Training program · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at baseline, week 6, week 12, month 6 and month 9
Closest Location: Groupe de recherche interdisciplinaire sur les maladies neuromusculaires · Saguenay, Canada
2013First Recorded Clinical Trial
3 TrialsResearching Myotonic Dystrophy
3 CompletedClinical Trials

Eligibility Criteria

Age 18+ · Female Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a woman aged between 30 and 65 years old.
You must live in the Saguenay-Lac-St-Jean region.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.